EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCs

In this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper explain that these agents are designed to target the TROP2 antigen on tumor cells and deliver a cytotoxic payload, enabling selective tumor cell killing. From a clinical perspective, they highlight that these therapies are being evaluated primarily in later-line settings following progression on EGFR tyrosine kinase inhibitors and other standard treatments. The panel discusses early efficacy signals, including response rates and durability, while also noting the importance of understanding safety profiles and potential toxicities associated with this class of agents. They emphasize that although these therapies show promise, their exact placement within treatment sequencing is still evolving. Overall, this segment highlights the growing interest in antibody–drug conjugates as a potential addition to the therapeutic landscape in EGFR-mutated NSCLC.